Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After losing some value lately, a hammer chart pattern has been formed for Medpace (MEDP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Medpace (MEDP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

This podcast helps make the world smarter, happier, and richer.

Checking In on Medpace, Autoliv, and 401(k) Plans

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2023 Earnings Conference Call July 25, 2023 9:00 AM ET Company Participants Lauren Morris - Director, IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants David Windley - Jefferies Max Smock - William Blair Sandy Draper - Guggenheim Partners Operator Good day, ladies and gentlemen, and welcome to the Medpace's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Medpace Holdings, Inc. (MEDP) Q2 2023 Earnings Call Transcript

Medpace (MEDP) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.90 per share. This compares to earnings of $1.46 per share a year ago.

Medpace (MEDP) Surpasses Q2 Earnings and Revenue Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Results Revenue for the three months ended June 30, 2023 increased 31.2% to $460.9 million, compared to $351.2 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2023 increased 31.0% compared to the second quarter of 2022. Backlog as of June 30, 2023 in.

Medpace Holdings, Inc. Reports Second Quarter 2023 Results

Medpace Holdings, a Clinical Research Organisation (CRO), has outperformed in the stock market with a return of 429% in the last five years compared to 62% for SPY. CROs, which develop clinical studies for pharma companies, have benefited from increased funding for clinical studies, particularly during the search for COVID vaccines. Despite a drop in biotech funding in 2021 and 2022, recent months have seen a sharp increase in funding levels, indicating a positive outlook for the industry and companies like Medpace.

Medpace: Resilience During The Down Cycle

Doximity

Inmode Ltd

Progyny

Doximity's massive platform for doctors is the perfect setting for healthcare advertisers. Declining fertility trends make Progyny's services all the more important to its customers.

4 Top Stocks to Buy in July and Hold Forever

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2023 financial results after the market close on Monday, July 24, 2023. The Company will host a conference call the following morning, Tuesday, July 25, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10.

Medpace Holdings, Inc. to Report Second Quarter 2023 Financial Results on July 24, 2023

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Medpace (MEDP) is a Great Momentum Stock: Should You Buy?

Cintas Corp

Kroger

E. W. Scripps

The latest earnings season has come and gone.

Cincinnati Earnings Roundup: Part 2

Shockwave Medical

Transmedics Group Inc

Healthcare technology stocks can be very lucrative investments. For evidence of that theory, take a look at the performances of three of the top names in the sector since August 2010.

Healthcare Technology: 3 Companies to Keep an Eye On Now

Apollo Medical Hlds

HealthEquity

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most.

3 Medical Services Stocks to Buy Amid Improving Industry Trends

Medpace is one the largest Clinical Research Organisations in the market, and consistently winning market share. On April 24, Medpace presented its earnings for the first quarter of FY23, showing operative strength in a challenging market environment.

Medpace: Gaining Market Share While Others Struggle

We've got a look at this company, what's going on with Pepsi, and other market news.

Medpace Holdings Crushed Analyst Expectations

You might be familiar with some of the brands, but the company's name is probably not on your radar.

Why MTY Food Group Is Worth a Look

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Medpace (MEDP) Rating Upgrade to Strong Buy

Medpace Holdings, Inc. (MEDP) Q1 2023 Earnings Call Transcript.

Medpace Holdings, Inc. (MEDP) Q1 2023 Earnings Call Transcript

Medpace (MEDP) came out with quarterly earnings of $2.27 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.69 per share a year ago.

Medpace (MEDP) Beats Q1 Earnings and Revenue Estimates

Medpace easily beat Wall Street's first-quarter projections late Monday and boosted its full-year outlook. In response, MEDP stock rocketed.

Medpace, A Top 1% Earnings Stock, Just Crushed Expectations — Here's A Key Measure To Watch

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Revenue for the three months ended March 31, 2023 increased 31.2% to $434.1 million, compared to $330.9 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2023 increased 31.8% compared to the first quarter of 2022. Backlog as of March 31, 2023 inc.

Medpace Holdings, Inc. Reports First Quarter 2023 Results

Strong financial growth in 2022, with healthy key performance metrics. Risks are contract cancellations, drug development unpredictability, and industry consolidation.

Medpace Holdings: Promising CRO With Strong Growth And Excellent Fundamentals

Cincinnati-based Medpace provides the biotechnology world with Phase 1-IV clinical development services using scientifically driven research. MEDP hit record Q4 2022 revenue of $394.1 million, indicating an increase of 27.7% (YoY), while full-year revenue of $1.46 billion represented a rise of 27.8% (Y/Y).

Medpace Holdings: Priced With High Expectations

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2023 financial results after the market close on Monday, April 24, 2023. The Company will host a conference call the following morning, Tuesday, April 25, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link.

Medpace Holdings, Inc. to Report First Quarter 2023 Financial Results on April 24, 2023

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q4 2022 Earnings Conference Call February 14, 2023 9:00 AM ET Company Participants Lauren Morris - IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants Sandy Draper - Guggenheim Partners Max Smock - William Blair David Windley - Jefferies John Sourbeer - UBS Eric Coldwell - RW Baird Operator Good day, ladies and gentlemen, and welcome to the Medpace Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Medpace Holdings, Inc. (MEDP) Q4 2022 Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 19.10% and 2.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Medpace Holdings Stock (MEDP)